Embecta makes pen needles, insulin syringes and safety injection devices for people with diabetes. EMBC reports earnings on Tue, Nov 24, 2026.
Prices, price targets and earnings estimates for EMBC are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in EMBC in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EMBC is in one of them and how their past EMBC trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Embecta
Embecta is a medical device company focused on helping people with diabetes manage insulin injections. Its main products are pen needles, insulin syringes and safety injection devices, which are designed to work with insulin pens and vials and to help protect users and healthcare workers from needlestick injuries. The company sells to patients, retailers, hospitals, pharmacies and other healthcare providers in many countries. It is based in Parsippany, New Jersey.
